RTW: Investing across Healthcare - [Business Breakdowns, EP.184]

Episode Summary

Executive Summary: The episode explores healthcare investing through RTW Investments’ public-private, science-driven approach. Rod Wong and Stephanie Sirota argue biotech is uniquely structured by long R&D cycles, binary outcomes, and rapid patent-driven revenue decay, making specialization, capital access, and MA essential. They highlight a new innovation boom in modalities like gene therapy and GLP-1s, while warning that policy changes like the IRA can distort incentives and slow drug development.

Main Topics: Why healthcare is structurally different (Priority: 5/5): Healthcare, especially drugs, has a three-stage lifecycle: long pre-revenue development, a strong but temporary revenue phase, and then rapid revenue collapse after patent expiry. This makes it unlike most sectors and harder to model with traditional valuation methods. RTW’s evolution into a specialist public-private investor (Priority: 5/5): RTW began as a public hedge fund but expanded into private markets to capture early scientific insight and better understand management teams and data before IPO. The firm built a large, multidisciplinary team to cover therapies, modalities, and transaction work. Innovation boom and new modalities (Priority: 5/5): The speakers describe a golden age of medicine driven by gene therapy, RNA, cell therapy, protein degraders, bispecifics, ADCs, and radiopharmaceuticals. They argue this wave is lifting new-drug approvals and expanding the opportunity set. Capital markets, funding, and the role of MA (Priority: 4/5): Because drug development is capital-intensive and lifecycle-driven, biotech depends on deep public markets and frequent M&A. Large pharma needs external innovation to refill pipelines, while smaller biotechs need exits to recycle capital. Policy, incentives, and the IRA (Priority: 5/5): They argue the Inflation Reduction Act shortens effective exclusivity for certain drugs, especially small molecules in elderly diseases, reducing expected returns and shifting capital away from some areas such as oncology. Valuation, timing, and investment process (Priority: 4/5): RTW frames investing as probability-weighting around upcoming events—clinical readouts, commercialization, and regulatory milestones. The best returns often come from getting in early and staying through multiple inflection points. GLP-1s and broader market effects (Priority: 3/5): GLP-1 drugs are portrayed as transformational for obesity, cardiovascular health, and longevity, but the near-term economic impact is likely gradual because reimbursement and adoption remain limited.

Key Arguments: Healthcare investing is different because drug products have no revenue for years, then a highly profitable but temporary commercial phase, then revenues fall off a cliff after patent expiry. Biotech is effectively 'venture capital in the public markets' because companies go public young and require enormous capital before revenue. Successful healthcare investors must combine scientific probability assessment, commercial forecasting, and capital-markets expertise. RTW’s public-private model creates an edge because private investing offers better access to management and scientific data, while much of the upside occurs after IPO. A specialized, collaborative team is necessary because modern biotech requires deep expertise across therapies, modalities, legal/financing, and operations. MA is not a side effect but a core feature of the healthcare system: big pharma must buy innovation to replace expiring products, and small biotechs need exits. The IRA has changed capital allocation by making some drug classes less attractive, especially small-molecule oncology, because reduced exclusivity lowers present value. Innovation is accelerating because new modalities are now producing approved drugs at scale, suggesting a sustained increase in annual approvals. GLP-1s should be viewed as a long-term health revolution, but the effect on consumer behavior and company earnings will take years, not quarters. Policy and reimbursement incentives matter greatly in biotech; poor incentives can suppress entire categories of drug development, as seen historically in antibiotics.

Data Points: AlphaSense market penetration: 75% of the world's top hedge funds - Sponsor mention at the beginning of the episode AlphaSense adoption: 85% of the SP 100 - Sponsor mention about platform users Premium source library: 400 million+ sources - AlphaSense sponsor description Expert transcript library: 150,000+ proprietary expert transcripts - AlphaSense sponsor description after Tegus acquisition Private market transcript share: 75% - AlphaSense claim about private market expert transcripts VC usage: 50% of VC firms on the Midas list - AlphaSense claim about conducting expert calls on the platform RTW founding year: 2009 - Introduction to RTW Investments Firm age: 15 years - Rod and Stephanie describe RTW's history Rod Wong experience: 20 years - Rod says he has been a healthcare investor for about 20 years RTW team size: 75 people worldwide - Stephanie describes the current organization Scientific degrees on team: north of two dozen - Rod notes terminal scientific degrees across the firm Average drug development timeline: ~15 years - Rod explains the typical journey from discovery to market NIH funding contribution per drug: a few hundred thousand to maybe $5 million of the ~$1 billion total - Private capital discussion of early-stage drug funding Total drug development cost: $1 billion+ - Rod describes the capital intensity of bringing a drug to market Average U.S. novel drug approvals historically: ~40 per year - Discussion of long-term approval rates before the recent surge Record U.S. novel drug approvals: 61 last year - They cite a recent all-time high Share of approvals from new modalities: just under 25% - Portion of last year's approvals attributed to newer modalities Forecast for future approvals: 80 to 100 per year - Rod and Stephanie predict approvals could rise over 5-10 years Potential share from new technologies: up to half - Projected portion of approvals from new modalities in 5-10 years Valiant share price/ownership dynamic: RTW was short for a good portion of the run-up - Rod explains their contrarian stance during the Valiant episode Valiant deal size: about a $500 million company pre-IPO - Stephanie recounts the Avexis example as a contrast to Valiant Avexis acquisition value: almost $9 billion - Rod describes the Novartis acquisition after gene therapy success Biotech bear market duration: 3 years - Rod says biotech has been in a bear market for the last three years Revenue exclusivity after IRA: 9 years for certain small molecules - Rod explains shortened commercial life for drugs used by the elderly Historical revenue exclusivity: ~14-15 years average - Industry average before IRA impact Large-company concentration example: Lilly and Novo combined have created roughly $1 trillion in value - Rod cites obesity-drug winners Global biopharma top-tier count: two dozen global biopharma companies - Rod discusses industry fragmentation at the top GLP-1 health benefit estimate: 20% to 30% - Rod cites early studies suggesting cardiovascular/health benefits U.S. overweight/diabetes base: plus or minus 10 million Americans on GLP-1s; another 20+ million diabetics, over 100 million overweight - Market adoption context for obesity drugs Biotech zero enterprise value share at peak: 35% to 37% of companies under $10B market cap - Rod describes sector distress during the bear market

Pivotal Quotes: "“Biotech is something that can really only exist in a very major way in America.”" — Rod Wong: Explaining why deep U.S. capital markets are essential for funding long, expensive drug development "“Drugs don't care whether they're in a public vehicle or a private vehicle.”" — Rod Wong: Justifying RTW's expansion from public equities into private investing "“The tragedy is that the narrative that's being dealt to people is: no one's going to price gouge on your cancer drug, but we don't actually know how many potential great small molecules are not going to be developed now because of this.”" — Stephanie Sirota: Critique of the IRA and its impact on innovation incentives

Implications: Listeners should see biotech as a specialized, event-driven asset class where science, capital access, and policy all matter. For the industry, innovation is accelerating, but incentives and reimbursement will shape what gets funded and who wins.